NCT04891809: Phase 2 - Isatuximab in Combination With Rd Compared to Rd in Elderly NDMM
What are Multiple myeloma defining events? International Myeloma Working Group - SLiM-CRAB Criteria
NCT04835129: Phase 2: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in RRMM (IMPEDE)
NCT04824794: Phase 1/2: GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction & Lenalidomide Maint
NCT04776395: Phase 2: Iberdomide Alone or in Combination With Dex for Intermediate/High-Risk SMM
THE MMRF - The Path to Precision Medicine in Multiple Myeloma
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in RRMM
NCT04717700: Phase 2: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dex in TIE NDMM
Patient Symposium - MCRT Webcast Myeloma Crowd Round Table, 04/10/2021
NCT04798586: Phase 1: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Patients Myeloma
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor MM
THE MMRF - Managing Myeloma Resource Brochure
THE MMRF - Multiple Myeloma Treatment Overview
NCCN GUIDELINES FOR PATIENTS: Immunotherapy Side Effects: CAR T-Cell Therapy
NCT04892446: Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory MM
NCT04920084: A Study of a Plant-Based Diet in People With MGUS / Smoldering Myeloma - NUTRIVENTION